Showing 1361-1370 of 2007 results for "".
- FDA Clears Full-Wavelength Capability for Lasermach Laser Systemhttps://modernaesthetics.com/news/fda-clears-full-wavelength-capability-for-lasermach-laser-system/2486382/Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://modernaesthetics.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A
- New Skin Quality Index Aims to Align Patient–Provider Communication in Aestheticshttps://modernaesthetics.com/news/new-skin-quality-index-aims-to-align-patientprovider-communication-in-aesthetics/2486112/Allergan Aesthetics, an AbbVie company, announced the launch of the Skin Quality Index (SQI), a new framework designed to standardize how patients and health care providers discuss skin quality during aesthetic consultations. The initiative is supported by global research published in Dermato
- Survey: 53% of Americans Would Sacrifice Everyday Spending for Aesthetic Treatmentshttps://modernaesthetics.com/news/survey-53-of-americans-would-sacrifice-everyday-spending-for-aesthetic-treatments/2486047/More than half of Americans say they would sacrifice everyday spending to afford non-surgical aesthetic procedures, according to a new national survey commissioned by LaserAway and conducted by Morning Consult among 2,202 US adults in February 2026. The findings highlight shifting consumer attitu
- Allergan Aesthetics Panel: Medical Weight Loss Fuels New Aesthetic Conversationshttps://modernaesthetics.com/news/allergan-aesthetics-panel-medical-weight-loss-fuels-new-aesthetic-conversations/2485952/Experts at Allergan Aesthetics’ “Navigating the New Era of Patient Needs” virtual event highlighted how GLP-1 receptor agonists (GLP-1 RAs) are changing facial aesthetic concerns, patient education, and treatment sequencing. Th
- Adipocytes Emerge as Central Drivers of Skin Aging in New Reviewhttps://modernaesthetics.com/news/adipocytes-emerge-as-central-drivers-of-skin-aging-in-new-review/2485879/A recent review in Biogerontology reframes skin aging by positioning adipocytes—particularly dermal white adipose tissue (dWAT)—as central regulators of age-related cutaneous change. Traditionally, skin aging has been attributed to epidermal and dermal alterations, including keratinocyte
- Photocurable Collagen Filler Aims to Address Weight-Loss–Associated Facial Deflationhttps://modernaesthetics.com/news/photocurable-collagen-filler-aims-to-address-weight-lossassociated-facial-deflation/2485851/CollPlant Biotechnologies announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA) for metabolic health and weight ma
- The Rise of Biostimulators: Complement, Not Competitor, in Aesthetic Regimenshttps://modernaesthetics.com/news/the-rise-of-biostimulators-complement-not-competitor-in-aesthetic-regimens/2485824/The filler category of medical aesthetics may have faced certain headwinds in 2025, but biostimulatory agents experienced a noticeable uptick. Still, at the 2026 Octane Aesthetics Tech Forum, “Flipping the Filler Script” panelists cautioned against viewing them as a replacement for hyaluronic aci
- Lynch Regenerative Medicine Names General Counsel, CMOhttps://modernaesthetics.com/news/lynch-regenerative-medicine-names-general-counsel-cmo/2485740/Lynch Regenerative Medicine (LRM), a regenerative medicine company focused on platelet-derived growth factor–based therapies, has named Madison Dini as General Counsel and Chad Lindemann as Chief Marketing Officer. According to the company, Dini will lead legal, compliance, and corporate g